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Vaccination with live attenuated SIV confers potent pro-
tection against wild-type SIV challenge in the SIV/
macaque model of HIV. Although safety concerns pre-
clude the direct application of this vaccine approach in
humans, a clearer understanding of its mechanism of pro-
tection may lead to the development of novel AIDS vac-
cines. A novel live attenuated SIVmac239 Δnef vaccine
(SIVrtTA), dependent on doxycycline administration for
replication, has been evaluated in vivo and its ability to
protect against pathogenic SIV challenge determined. Two
groups of six Indian rhesus macaques (Groups A and B)
were vaccinated with SIVrtTA with an oral doxycycline
dosing regime for 6 months. In Group A, doxycycline was
stopped for 8 weeks before wtSIVmac239 challenge. A
third group was vaccinated with a conventional
SIVmac239Δnef vaccine. In the presence of doxycycline,
all 12 macaques receiving SIVrtTA were infected exhibit-
ing peak SIV RNA levels (log10 3-5 SIV RNA copies/ml)
which declined in all macaques but persisted at higher lev-
els in three SIVrtTA vaccinates. Levels of virus replication
measured by independent qRT-PCR and qDNA PCR
assays were lower in SIVrtTA vaccinates compared with
the SIVmac239Δnef vaccine which peaked in the log10 4-6
SIV RNA copies/ml range. No escape from doxycycline
dependence was identified. Upon challenge with wild-
type SIVmac239 and compared with naive challenge con-
trols (Group D), a significant vaccine effect was observed
in all three vaccine groups, assessed by the comparative
reduction of circulating viral RNA in plasma. Naive
wtSIVmac239 challenge controls exhibited ~7 log10 SIV
RNA copies/ml at peak which persisted beyond the acute
infection phase. This compared with all three vaccine
groups where post wtSIVmac239 viral RNA levels were
markedly reduced among SIVrtTA vaccinates with a more
pronounced vaccine effect among Group A vaccinates.
Viral RNA was un-detectable in one SIVrtTA vaccinate
(Group A) and in the 2 log10 range in another (Group B).
The highest levels of protection in SIVrtTA vaccinates cor-
related with an enhanced persistence of SIVrtTA as circu-
lating viral RNA in the immediate post-acute infection
vaccine period. Retrospective sequence analysis recovered
from SIVrtTA vaccinates indicated a selection of sequence
variants in the LTR promoter region and the Tat and rtTA
genes that do not affect doxycycline control but which
may have influenced replication in vivo. Vaccination with
SIVrtTA induced a marked vaccine effect which will enable
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the role of viral persistence to be evaluated in this vaccina-
tion strategy. SIVrtTA represents a new tool to develop and
design novel AIDS vaccines.